Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as- sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna- ceuticals. Experts from academia, industry, and regulatory authori- ties were invited to give presentations on aspects covering the identi- fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men- tioned target validation studies.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Bookbot, Prague, Rébublique tchèque
Hardcover. Etat : As New. Originalverpackt. Inhaltsverzeichnis1 Molecular Imaging: Dream or Reality?.2 Target Discovery and Validation.3 Noninvasive Imaging in Drug Discovery and Development.4 Internal Dose Assessment -- Extrapolation from Animal Species to the Human.5 PET for Drug Development.6 Future Directions in Molecular Imaging.7 Regulatory Implications -- The EU Perspective.8 Nonclinical Development of Radiopharmaceuticals: Regulatory Considerations for the United States Food and Drug Administration.9 The Japanese Perspective on Radiopharmaceuticals.Previous Volumes Published in This Series. N° de réf. du vendeur 7ccc325e-f049-4faf-bdd7-20f30c2fbf57
Quantité disponible : 1 disponible(s)
Vendeur : Book Broker, Berlin, Allemagne
Etat : Wie neu. 2004. 209 S. Alle Bücher & Medienartikel von Book Broker sind stets in gutem & sehr gutem gebrauchsfähigen Zustand. Dieser Artikel weist folgende Merkmale auf: Helle/saubere Seiten in fester Bindung. Sprache: Englisch Gewicht in Gramm: 524 Gebundene Ausgabe, Maße: 16 cm x 1.78 cm x 23.88 cm. N° de réf. du vendeur 661010486
Quantité disponible : 1 disponible(s)
Vendeur : Antiquariat Kretzer, Kirchhain-Emsdorf, Allemagne
Etat : Sehr gut. XIII, 191 Seiten. Mit 20 Figuren. Very good copy. ISBN: 3540201378 Sprache: Englisch Gewicht in Gramm: 990 8° (17,5-22,5 cm). Orig.-Pappband. [Hardcover / fest gebunden]. N° de réf. du vendeur 99047
Quantité disponible : 1 disponible(s)
Vendeur : ralfs-buecherkiste, Herzfelde, MOL, Allemagne
Hardcover 22x15. Etat : Gut. 191 Seiten gut bis sehr gut erhaltenes Exemplar, Buch ist noch verschweißt ha1006908 Sprache: Englisch Gewicht in Gramm: 450. N° de réf. du vendeur 108470
Quantité disponible : 1 disponible(s)
Vendeur : Buchpark, Trebbin, Allemagne
Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna ceuticals. Experts from academia, industry, and regulatory authori ties were invited to give presentations on aspects covering the identi fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men tioned target validation studies. N° de réf. du vendeur 1527482/202
Quantité disponible : 2 disponible(s)
Vendeur : ralfs-buecherkiste, Herzfelde, MOL, Allemagne
Hardcover 22x15. Etat : Gut. 191 Seiten gut bis sehr gut erhaltenes Exemplar, Buch ist noch verschweißt ha1006883 Sprache: Englisch Gewicht in Gramm: 450. N° de réf. du vendeur 108445
Quantité disponible : 1 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783540201373_new
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 2525074-n
Quantité disponible : 15 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna ceuticals. Experts from academia, industry, and regulatory authori ties were invited to give presentations on aspects covering the identi fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men tioned target validation studies. 212 pp. Englisch. N° de réf. du vendeur 9783540201373
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Gebunden. Etat : New. N° de réf. du vendeur 4884490
Quantité disponible : Plus de 20 disponibles